A new experimental product, SGN-35, which is manufactured by Seattle Genetics Inc. and Takeda Pharmaceutical Co., combines a tumor-killing chemical, with a cancer-killing antibody. The new medication cleared cancer to untraceable levels in 53% of patients suffering from anaplastic large cell lymphoma and cut tumor size by at least half in an additional 33%.

Anaplastic large cell lymphoma is a rare type of non-Hodgkin lymphoma where a tumor develops in lymph tissue or various organs, and usually contains many white blood cells. This type of lymphoma only affects approximately 600 to 700 patients per year. Symptoms include swollen lymph nodes, neck lumps, night sweats, and extreme fatigue.

According to Bloomberg, "SGN-35 works by using an antibody to bond with a protein found on the surface of lymphoma cells, and blasts them with auristatin, a chemical that kills cancer by blocking cell division."